Travere Therapeutics (TVTX) Tops Q2 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- S&P 500 up, Nasdaq at record high as megacap tech stocks rise
- Oil slips on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailGet Alerts TVTX Hot Sheet
Join SI Premium – FREE
Travere Therapeutics (NASDAQ: TVTX) reported Q2 EPS of ($0.14), $0.16 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $114.4 million versus the consensus estimate of $99.25 million.
For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alethia Capital Starts TTM Technologies (TTMI) at Overweight, 'A Unique Proxy Standing for USA PCB'
- Dr. Steven Shannon Scholarship for Medical Students Opens Applications to Support Future Healthcare Leaders
- BTIG Reiterates Buy Rating on Vaxcyte (PCVX)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
